Dow Jones

43,449.90

-0.61%

Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

Regístrate

RNA

Avidity Biosciences (RNA)

Avidity Biosciences Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:RNA

1 2 3 4 5 6 7 8 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
16/12/2024	15:29	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:RNA	Avidity Biosciences Inc
13/12/2024	17:08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RNA	Avidity Biosciences Inc
26/11/2024	09:00	PR Newswire (US)	Avidity Biosciences to Participate in Upcoming Investor Conference	NASDAQ:RNA	Avidity Biosciences Inc
21/11/2024	15:05	PR Newswire (US)	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:RNA	Avidity Biosciences Inc
14/11/2024	08:39	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:RNA	Avidity Biosciences Inc
13/11/2024	15:40	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:RNA	Avidity Biosciences Inc
12/11/2024	06:06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RNA	Avidity Biosciences Inc
12/11/2024	06:00	PR Newswire (US)	Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations	NASDAQ:RNA	Avidity Biosciences Inc
07/11/2024	15:05	PR Newswire (US)	Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights	NASDAQ:RNA	Avidity Biosciences Inc
31/10/2024	08:00	PR Newswire (US)	Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024	NASDAQ:RNA	Avidity Biosciences Inc
30/10/2024	07:00	PR Newswire (US)	Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy	NASDAQ:RNA	Avidity Biosciences Inc
03/10/2024	06:00	PR Newswire (US)	Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)	NASDAQ:RNA	Avidity Biosciences Inc
05/09/2024	08:00	PR Newswire (US)	Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month	NASDAQ:RNA	Avidity Biosciences Inc
28/08/2024	08:00	PR Newswire (US)	Avidity Biosciences to Participate in Upcoming Investor Conferences	NASDAQ:RNA	Avidity Biosciences Inc
19/08/2024	08:00	PR Newswire (US)	Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares	NASDAQ:RNA	Avidity Biosciences Inc
15/08/2024	15:43	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:RNA	Avidity Biosciences Inc
14/08/2024	19:30	PR Newswire (US)	Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock	NASDAQ:RNA	Avidity Biosciences Inc
09/08/2024	16:02	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:RNA	Avidity Biosciences Inc
09/08/2024	15:23	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:RNA	Avidity Biosciences Inc
09/08/2024	15:05	PR Newswire (US)	Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights	NASDAQ:RNA	Avidity Biosciences Inc
09/08/2024	06:00	PR Newswire (US)	Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in	NASDAQ:RNA	Avidity Biosciences Inc
05/08/2024	08:00	PR Newswire (US)	Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer	NASDAQ:RNA	Avidity Biosciences Inc
20/06/2024	08:00	PR Newswire (US)	Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day	NASDAQ:RNA	Avidity Biosciences Inc
17/06/2024	15:05	PR Newswire (US)	Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares	NASDAQ:RNA	Avidity Biosciences Inc
13/06/2024	19:00	PR Newswire (US)	Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock	NASDAQ:RNA	Avidity Biosciences Inc
12/06/2024	15:01	PR Newswire (US)	Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock	NASDAQ:RNA	Avidity Biosciences Inc
12/06/2024	06:00	PR Newswire (US)	Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy	NASDAQ:RNA	Avidity Biosciences Inc
29/05/2024	15:05	PR Newswire (US)	Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress	NASDAQ:RNA	Avidity Biosciences Inc
16/05/2024	17:15	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:RNA	Avidity Biosciences Inc
15/05/2024	08:10	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:RNA	Avidity Biosciences Inc